DT-Web

DB00287 - Travoprost


Identification
Name Travoprost
Accession Number DB00287 (APRD01271)
Type small molecule
Description Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a synthetic prostaglandin F2alpha analogue. [Wikipedia]
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 500.5477
Groups approved
Monoisotopic Weight 500.238573467
Pharmacology
Indication Ophthalmic solution used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.
Mechanism of action Travoprost free acid is a selective FP prostanoid receptor agonist and is believed to reduce intraocular pressure by increasing the drainage of aqueous humor, which is done primarily through increased uveoscleral outflow and to a lesser extent, trabecular outflow facility.
Absorption Systemically absorbed when administered to the eye.
Protein binding Not Available
Biotransformation Travoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to its biologically active free acid. Systemically, travoprost free acid is metabolized to inactive metabolites via beta-oxidation of the α(carboxylic acid) chain to give the 1,2-dinor and 1,2,3,4-tetranor analogs, via oxidation of the 15-hydroxyl moiety, as well as via reduction of the 13,14 double bond.
Route of elimination Less than 2% of the topical ocular dose of travoprost was excreted in the urine within 4 hours as the travoprost free acid.
Toxicity Symptoms of overexposure include irritation to the skin, eyes, nose, throat, and respiratory tract.
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions Not Available
Food Interactions Not Available

Targets


Prostaglandin F2-alpha receptor
Name Prostaglandin F2-alpha receptor
Gene Name PTGFR
Pharmacological action yes
Actions agonist
References
  • Ota T, Aihara M, Narumiya S, Araie M: The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4159-63. - Pubmed
  • Thieme H, Schimmat C, Munzer G, Boxberger M, Fromm M, Pfeiffer N, Rosenthal R: Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci. 2006 Mar;47(3):938-45. - Pubmed
  • Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.e4. - Pubmed
  • Neacsu AM: [Receptors involved in the mechanism of action of topical prostaglandines] Oftalmologia. 2009;53(2):3-7. - Pubmed
  • Costagliola C, dell'Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F: Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother. 2009 Dec;10(17):2859-70. - Pubmed
  • Ferrari G, Scagliotti GV: Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients. Eur J Cancer. 1996 Dec;32A(13):2368-9. - Pubmed
  • Toris CB, Gabelt BT, Kaufman PL: Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008 Nov;53 Suppl1:S107-20. - Pubmed
  • Arranz-Marquez E, Teus MA: Prostanoids for the management of glaucoma. Expert Opin Drug Saf. 2008 Nov;7(6):801-8. - Pubmed
  • Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. - Pubmed
DTHybrid score 0.7359

Predictions


Id Partner name Gene Name Score
4131 Prostaglandin E2 receptor, EP3 subtype PTGER3 0.0703
290 Prostaglandin G/H synthase 2 PTGS2 0.0667
73 Prostaglandin E2 receptor, EP1 subtype PTGER1 0.0603
650 Aldo-keto reductase family 1 member C3 AKR1C3 0.0529
1632 Solute carrier organic anion transporter family member 2B1 SLCO2B1 0.0522
6145 Solute carrier family 22 member 1 SLC22A1 0.0431
527 Prostacyclin receptor PTGIR 0.0298
6160 Solute carrier organic anion transporter family member 3A1 SLCO3A1 0.0233
6152 Solute carrier organic anion transporter family member 2A1 SLCO2A1 0.0217
1024 Solute carrier family 22 member 11 SLC22A11 0.0165
6143 Solute carrier family 22 member 7 SLC22A7 0.0162
6144 Solute carrier family 22 member 2 SLC22A2 0.0149
6142 Solute carrier family 22 member 8 SLC22A8 0.0142
1729 Solute carrier family 22 member 6 SLC22A6 0.013
↑